Background: Little is known about the role of WNT signalling in pathological processes involving the urinary tract stroma. Here the impact of WNT signalling on bladder wall fibroblasts (BWFs) was studied using integrated expression profiling. Material and Methods: WNT ligand and downstream WNT pathway component expression was profiled in human BWFs using qRT-PCR. Highly expressed WNT2B was knocked down using siRNA in BWFs. The expression of 730 mRNAs and 800 miRNAs was analyzed on the nCounter MAX platform in #WNT2B and control transfected BWFs. qRT-PCR was used for validation in vitro and in matched scar and healthy bladder wall tissue samples of 12 patients with vesico-urethral anastomotic stricture (VUAS). Results: Thirteen genes and 9 miRNAs showed differential expression in #WNT2B cells. Among these were TNFSF10, a key apoptosis inductor, (0.22fold, p = 0.011) and miR-1246 (36.2fold, p = 0.031). miRNA target prediction indicated TNFSF10 to be regulated by miR-1246. qRT-PCR analysis confirmed differential expression of miR-1246 and TNFSF10 in #WNT2B BWFs. Furthermore, TNFSF10 was significantly underexpressed in VUAS tissue (p = 0.009). Conclusion: Perturbation of WNT signalling results in an altered expression of the apoptosis inductor TNFSF10. Similar changes are observed in VUAS. Further studies investigating the crosslink between WNT signalling and apoptosis regulation in the urinary tract stroma are warranted.

Keywords:
Urinary tract, Stroma, Fibroblasts, WNT signalling, mRNA expression, miRNA expression, Nanostring, TNFSF10, Apoptosis, Vesico-urethral anastomotic stricture
1.
Wend P, Holland JD, Ziebold U, Birchmeier W: Wnt signaling in stem and cancer stem cells. Semin Cell Dev Biol 2010; 21: 855–863.
2.
Asem MS, Buechler S, Wates RB, Miller DL, Stack MS: Wnt5a signaling in cancer. Cancers (Basel) 2016; 8:pii:E79.
3.
Baarsma HA, Königshoff M, Gosens R: The WNT signaling pathway from ligand secretion to gene transcription: molecular mechanisms and pharmacological targets. Pharmacol Ther 2013; 138: 66–83.
4.
Krausova M, Korinek V: Wnt signaling in adult intestinal stem cells and cancer. Cell Signal 2014; 26: 570–579.
5.
Semenov MV, Habas R, Macdonald BT, He X: SnapShot: noncanonical Wnt signaling pathways. Cell 2007; 131: 1378.
6.
van Amerongen R, Nusse R: Towards an integrated view of Wnt signaling in development. Dev Camb Engl 2009; 136: 3205–3214.
7.
Halt K, Vainio S: Coordination of kidney organogenesis by Wnt signaling. Pediatr Nephrol Berl Ger 2014; 29: 737–744.
8.
Goggolidou P: Wnt and planar cell polarity signaling in cystic renal disease. Organogenesis 2014; 10: 86–95.
9.
Kawakami T, Ren S, Duffield JS: Wnt signalling in kidney diseases: dual roles in renal injury and repair. J Pathol 2013; 229: 221–231.
10.
Bohnenpoll T, Kispert A: Ureter growth and differentiation. Semin Cell Dev Biol 2014; 36: 21–30.
11.
Baranowska Körberg I, Hofmeister W, Markljung E, Cao J, Nilsson D, Ludwig M, et al: WNT3 involvement in human bladder exstrophy and cloaca development in zebrafish. Hum Mol Genet 2015; 24: 5069–5078.
12.
Bouty A, Ayers KL, Pask A, Heloury Y, Sinclair AH: The genetic and environmental factors underlying hypospadias. Sex Dev 2015; 9: 239–259.
13.
Ahmad I, Morton JP, Singh LB, Radulescu SM, Ridgway RA, Patel S, et al: β-Catenin activation synergizes with PTEN loss to cause bladder cancer formation. Oncogene 2011; 30: 178–189.
14.
Ahmad I: The role of WNT signalling in urothelial cell carcinoma. Ann R Coll Surg Engl 2015; 97: 481-486.
15.
Zhang K, Guo X, Zhao W, Niu G, Mo X, Fu Q: Application of Wnt pathway inhibitor delivering scaffold for inhibiting fibrosis in urethra strictures: in vitro and in vivo study. Int J Mol Sci 2015; 16: 27659–27676.
16.
Cisternas P, Vio CP, Inestrosa NC: Role of Wnt signaling in tissue fibrosis, lessons from skeletal muscle and kidney. Curr Mol Med 2014; 14: 510–522.
17.
Matsushima K, Suyama T, Takenaka C, Nishishita N, Ikeda K, Ikada Y, et al: Secreted frizzled related protein 4 reduces fibrosis scar size and ameliorates cardiac function after ischemic injury. Tissue Eng Part A 2010; 16: 3329–3341.
18.
Smith JC, Boone BE, Opalenik SR, Williams SM, Russell SB: Gene profiling of keloid fibroblasts shows altered expression in multiple fibrosis-associated pathways. J Invest Dermatol 2008; 128: 1298–1310.
19.
van Dijk EM, Menzen MH, Spanjer AIR, Middag LDC, Brandsma CA, Gosens R: Noncanonical WNT-5B signaling induces inflammatory responses in human lung fibroblasts. Am J Physiol Lung Cell Mol Physiol 2016; 310:L1166–1176.
20.
Worst TS, Daskalova K, Steidler A, Berner-Leischner K, Röth R, Niesler B, et al: Novel insights into a reputably irreversible process: combined mRNA and miRNA profiling of tissue from vesicourethral anastomotic stenosis after radical prostatectomy. World J Urol 2017, Epub ahead of print.
21.
Untergasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, Remm M, et al: Primer3–new capabilities and interfaces. Nucleic Acids Res 2012; 40:e115.
22.
Castellone MD, Laukkanen MO: TGF-beta1, WNT, and SHH signaling in tumor progression and in fibrotic diseases. Front Biosci (Sch Ed) 2017; 9: 31–45.
23.
Bayle J, Fitch J, Jacobsen K, Kumar R, Lafyatis R, Lemaire R: Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol 2008; 128: 871–881.
24.
Sato M: Upregulation of the Wnt/beta-catenin pathway induced by transforming growth factor-beta in hypertrophic scars and keloids. Acta Derm Venereol 2006; 86: 300–307.
25.
Crowder RN, Dicker DT, El-Deiry WS: The Deubiquitinase inhibitor PR-619 sensitizes normal human fibroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cell death. J Biol Chem 2016; 291: 5960–5970.
26.
Audo R, Hegglin A, Severac D, Dantec C, Combe B, Hahne M, et al: Identification of genes regulating TRAIL-induced apoptosis in rheumatoid arthritis fibroblasts-like synoviocytes. Genes Immun 2015; 16: 462–469.
27.
Emblom-Callahan MC, Chhina MK, Shlobin OA, Ahmad S, Reese ES, Iyer EPR, et al: Genomic phenotype of non-cultured pulmonary fibroblasts in idiopathic pulmonary fibrosis. Genomics 2010; 96: 134–145.
28.
Hasel C, Dürr S, Rau B, Sträter J, Schmid RM, Walczak H, et al: In chronic pancreatitis, widespread emergence of TRAIL receptors in epithelia coincides with neoexpression of TRAIL by pancreatic stellate cells of early fibrotic areas. Lab Investig J Tech Methods Pathol 2003; 83: 825–836.
29.
Griesmann H, Ripka S, Pralle M, Ellenrieder V, Baumgart S, Buchholz M, et al: WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer. Neoplasia 2013; 15: 11–22.
30.
Zimmerman ZF, Kulikauskas RM, Bomsztyk K, Moon RT, Chien AJ: Activation of Wnt/β-catenin signaling increases apoptosis in melanoma cells treated with trail. PloS One 2013; 8:e69593.
31.
Engelsvold DH, Utheim TP, Olstad OK, Gonzalez P, Eidet JR, Lyberg T, et al: miRNA and mRNA expression profiling identifies members of the miR-200 family as potential regulators of epithelial-mesenchymal transition in pterygium. Exp Eye Res 2013; 115: 189–198.
32.
Kim G, An HJ, Lee MJ, Song JY, Jeong JY, Lee JH, et al: Hsa-miR-1246 and hsa-miR-1290 are associated with stemness and invasiveness of non-small cell lung cancer. Lung Cancer Amst Neth 2016; 91: 15–22.
33.
Liao JM, Zhou X, Zhang Y, Lu H: MiR-1246: a new link of the p53 family with cancer and Down syndrome. Cell Cycle 2012; 11: 2624–2630.
34.
Wiatr T, Golabek T, Dudek P, Belch L, Przydacz M, Bukowczan J, et al: Single running suture versus single-knot running suture for vesicourethral anastomosis in laparoscopic radical prostatectomy: a prospective randomised comparative study. Urol Int 2015; 95: 445–451.
35.
Good DW, Wood A, Stewart L, Stolzenburg JU, Ganzer R, Neuhaus J, et al: Striated muscle in radical prostatectomy specimens: a marker of apical dissection quality and an independent predictor of urinary continence after endoscopic extraperitoneal radical prostatectomy. Urol Int 2017; 98: 71–78.
36.
Surya BV, Provet J, Johanson KE, Brown J: Anastomotic strictures following radical prostatectomy: risk factors and management. J Urol 1990; 143: 755–758.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.